Čájehuvvojit 1 - 3 oktiibuot 3 bohtosis ohcui Richard J. Nowak', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial

    Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial Dahkki Richard J Nowak, Samantha G Brew, Molly Frey, Derrick P McCarthy, Adam Elhofy

    Almmustuhtton 2024-12-01
    Viečča ollesdeavstta
    Artihkal
  2. 2
    US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

    US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization Dahkki Richard J. Nowak, Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, S. Chloe Sader, Alexandrina Balanean, Ajeet Gajra, James F. Howard, ELEVATE Study Group

    Almmustuhtton 2024-10-01
    Viečča ollesdeavstta
    Artihkal
  3. 3
    Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination

    Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination Dahkki Marc Garbey, Marc Garbey, Marc Garbey, Quentin Lesport, Quentin Lesport, Helen Girma, Gülşen Öztosun, Mohammed Abu-Rub, Amanda C. Guidon, Vern Juel, Richard J. Nowak, Betty Soliven, Inmaculada Aban, Henry J. Kaminski

    Almmustuhtton 2024-12-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: